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Abstract 
Background 
Hippocampal neurogenesis has been suggested as a downstream event of 
antidepressants (AD) mechanism of action and might explain the lag time 
between AD administration and the therapeutic effect. Despite the widespread 
use of AD in the context of Major Depressive Disorder (MDD) there are no 
reliable biomarkers of treatment response phenotypes, and a significant 
proportion of patients display Treatment Resistant Depression (TRD). 
Fas/FasL system is one of the best-known death-receptor mediated cell 
signaling systems and is recognized to regulate cell proliferation and tumor cell 
growth. Recently this pathway has been described to be involved in 
neurogenesis and neuroplasticity. 
Methods 
Since FAS -670A>G and FASL -844T>C functional polymorphisms never been 
evaluated in the context of depression and antidepressant therapy, we 
genotyped FAS -670A>G and FASL -844T>C in a subset of 80 MDD patients to 
evaluate their role in antidepressant treatment response phenotypes. 
Results 
We found that the presence of FAS -670G allele was associated with 
antidepressant bad prognosis (relapse or TRD: OR=6.200; 95% CI: [1.875–
20.499]; p=0.001), and we observed that patients carrying this allele have a 
higher risk to develop TRD (OR=10.895; 95% CI: [1.362–87.135]; p=0.008). 
Moreover, multivariate analysis adjusted to potentials confounders showed that 
patients carrying G allele have higher risk of early relapse (HR=3.827; 95% CI: 
[1.072–13.659]; p=0.039). FAS mRNA levels were down-regulated among G 
carriers, whose genotypes were more common in TRD patients. No association 
was found between FASL-844T>C genetic polymorphism and any treatment 
phenotypes. 
Limitations 
Small sample size. Patients used antidepressants with different mechanisms of 
action. 
Conclusion 
To the best of our knowledge this is the first study to evaluate the role 
of FAS functional polymorphism in the outcome of antidepressant therapy. This 
preliminary report associates FAS -670A>G genetic polymorphism with 
Treatment Resistant Depression and with time to relapse. The current results 
may possibly be given to the recent recognized role of Fas in neurogenesis 
and/or neuroplasticity. 
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1. Introduction 
The Fas/FasL system, also known as CD95 or APO-1, is one of the 
major apoptotic pathways, mediating cell cytotoxicity, immune cell regulation 
and tumor cell growth (Lambert et al., 2003, Suda et al., 1993 and Trauth et al., 
1989). Fas, a cell surface receptor, interacts with its natural ligand FasL 
(CD95L) to initiate a death signaling cascade, leading to apoptosis. Whereas 
Fas is ubiquitously expressed and particularly abundant in liver, heart, kidney, 
pancreas, brain, thymus, lymphoid tissues, and activated mature T 
lymphocytes, it's ligand is predominantly expressed in activated T lymphocytes 
and NK cells, mediating immune cell clearance (Guicciardi and Gores, 
2009, Oshimi et al., 1996 and Suda et al., 1995). In brain, Fas expression has 
been documented in cortical, hippocampal, sensory, and motorneurons, and in 
all types of glial cells. Fas-mediated apoptosis is responsible for the neural and 
glial cells clearance upon brain injury, such as stroke and spinal cord damage 
(Zuliani et al., 2006). Further than apoptosis, Fas/FasL has emerged as an 
important regulator of a widespread of non-apoptotic functions, as cell 
activation, proliferation and differentiation, in several cell types (Barca et al., 
2013, Lambert et al., 2003 and Wajant et al., 2003). Recent studies point out 
novel functions of Fas pathway in brain, such as dendritic branching of 
immature neurons, axonal elongation in dorsal root ganglia cells, migration of 
glioblastoma cells and neurogenesis in the adult brain (Corsini et al., 
2009, Desbarats et al., 2003, Kleber et al., 2008 and Zuliani et al., 2006). 
Authors claimed that activation of death or regeneration pathways seemed to be 
influence by the surrounding context, such as the presence of growth factors, 
expression of pro-apoptotic molecules (caspase 8), pro-survival proteins (Akt) 
and by oxidative stress (Lambert et al., 2003). 
The relationship among hippocampal neurogenesis, depression and 
the antidepressants mechanism of action has generated a considerable amount 
of interest and controversy. Despite antidepressant drugs produce a rapid 
increase in neurotransmitters synaptic levels, clinical improvement usually takes 
3–4 weeks to be observed (Frazer and Benmansour, 2002). This is thought to 
be explained by the “neuroplasticity hypothesis” of depression, where stress 
decreases hippocampal neurogenesis and/or synaptic plasticity in prefrontal 
cortex (Pilar-Cuellar et al., 2013), and antidepressant treatment stimulates 
neurogenesis and/or neuronal plasticity (Duman and Monteggia, 2006). It is 
known that the maturation of newly developed neurons requires about 3–4 
weeks. Moreover, different classes of antidepressants stimulate the proliferation 
of neuronal progenitors (Duman, 2004, Malberg, 2004 and Malberg et al., 2000) 
and increase the survival of newly developed neurons (Wang et al., 2008). In 
addition, ablation of neurogenesis by irradiation reduces some of the 
antidepressants effects (Santarelli et al., 2003). Thus, intact hippocampal 
neurogenesis is required for at least some of the behavioral effects of 
antidepressants in animal models. 
Despite the widespread of antidepressants available in the clinical context, a 
wide fraction of patients fail to remit to treatment, and some display Treatment 
Resistant Depression (TRD). Identifying patients at risk of treatment resistance 
using biomarkers could possibly have direct impact on individualized therapy. 
Even though this is an area of increase investigation, the studied biological 
markers only explain a small fraction of the therapeutic outcome and are seek 
for biomarkers of response, not remission, the most important clinical outcome. 
Taking in consideration the link between neurogenesis and the mechanism of 
action of antidepressant drugs, and the recent recognized function of Fas/FasL 
system in neurogenesis and neuritogenesis, it may be hypothesized that the 
variability of AD therapeutic effect may be influenced by differential expression 
of Fas/FasL system. Functional polymorphisms in the promoter region 
of FAS and FASL genes are known to alter the transcriptional activity of these 
genes. One is an A to G substitution in -670 position of FAS gene, which 
decreases activity of FAS gene promoter and consequently reduces Fas 
receptor expression ( Huang et al., 1997, Kanemitsu et al., 2002 and Sibley et 
al., 2003). Another is a thymine (T) to cytosine (C) transition at position -844 of 
theFASL gene, which is associated with an higher basal expression of FasL 
( Lima et al., 2014 and Wu et al., 2003). These functional polymorphisms have 
been associated with a higher risk of cancer development in various models 
( Zhang et al., 2009a and Zhang et al., 2009b). In neuropsychiatric diseases, 
one SNP and two haplotypes in FAS gene have been associated with treatment 
resistant schizophrenia ( Jia et al., 2011). Despite the recent implications of Fas 
in neuroplasticity and neurogenesis, and the importance of these phenomena in 
depression and antidepressant treatment, FAS polymorphisms never been 
studied in the context of depression and antidepressant response. 
In this circumstance, we aim to evaluate the role of FAS -670A>G and FASL -
844T>Cfunctional polymorphisms in antidepressant treatment 
response phenotypes. 
2. Material and methods 
2.1. Patients 
The cohort included participants followed in a 27 months-follow-up study at 
Hospital Magalhães Lemos (HML) (Carvalho, 2012). Patients with the suspicion 
of depression were sent to the HML by their family doctor and those whose 
clinical interview confirmed the diagnosis of depression were submitted to 
further evaluation for major depressionusing the Structured Clinical Interview 
for DSM Axis I Disorders (SCID-I), and for personality disorders using the Axis II 
Disorders (SCID-II). Severity of the depressive symptoms was evaluated 
with Beck Depression Inventory (BDI), we used a cut-off of 20 as the point for 
entry into this study, since the goal was to include moderate to severe 
major depressive episodes. Subjects with more than one previous depressive 
episode, severe physical illness, psychiatric disorders with non-depressive 
psychotic symptoms, substance dependence or personality disorders were 
excluded from the study. From a total of 92 Portuguese MDD patients which full 
field the referred criteria, 80 patients agreed to participate in the genetic study. 
This cohort included 21 males and 59 females, aged from 18 to 60 years, with a 
median age of 41.5 years old (mean age 40.48; standard deviation 11.06). 
Patients were treated according to the Texas Medication Algorithm (Trivedi et 
al., 2004). Clinical response to adequate antidepressant treatment 
(administered after at least 6 weeks and at adequate doses) was measured by 
Beck Depression Inventory (BDI) score. Patients who had a BDI score less than 
10 after 6 weeks of at least one single adequate antidepressant treatment and 
absence of criteria of Major Depression according to SCID-I, were defined as 
remitters. The treatment outcome phenotype was defined as ‘Treatment 
Resistant Depression' when the patient failed to reach a BDI score less than 10 
and present criteria of Major Depression according to SCID-I, after at least two 
adequate antidepressant treatments with different drugs within the current 
episode. Relapse was defined as any depressive episode during the 24-month 
follow up. Bad Prognosis was considered when patient displayed Treatment 
Resistant Depression or relapsed. The study was approved by the ethical 
committee of Hospital Magalhães Lemos, and written informed consent 
according to “The Code of Ethics of the World Medical Association” (Declaration 
of Helsinki) was obtained from each individual after explanation of the study. 
2.2. DNA extraction and FAS -670G>A and FASL -844T>C polymorphism 
analysis 
Peripheral blood samples were collected following standard venipuncture 
technique in EDTA containing tubes, and the genomic DNA was extracted from 
the whole blood with a commercial kit (E.Z.N.A. – Omega Bio-tek, Norcross, 
USA), according to the manufacturer's instructions and stored at −20 °C. 
The FAS -670G>A (rs1800682) and FASL -844T>C (rs763110) polymorphisms 
were determined using a Sequenom MassARRAY system (San Diego, CA, 
USA). The genotyping was undertaken using the SequenomiPLEX platform, 
according to the manufacturer's instructions (Sequenom, San Diego, CA, USA). 
The detection of SNPwas carried out by analyzing the primer extension 
products generated from previously amplified genomic DNA using a Sequenom 
chip-based matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry platform. Sequenom Assay Design 3.1 software was 
used to design the primers for polymerase chain reaction (PCR) amplification 
and single base extension assays (Sequenom, San Diego, CA, USA) according 
to the manufacturer's instructions. Genotyping data was read blindly to the 
study endpoint. For quality control, 10% of the samples were randomly selected 
for a second analysis and 100% of concordance was observed. 
2.3. RNA extraction and FASL mRNA expression analysis 
FAS mRNA expression was analyzed in peripheral blood samples collected 
from a subset of 38 patients at the end of the study. The subset of patients 
included 30 remitters and 8 patients with TRD. Patients were similar regarding 
age, gender and the lastpsychotropic drugs prescribed prior to blood draw 
(p>0.05). Whole blood was recovered from patients between 8.30 and 
12.30 a.m. RNA was isolated from blood leukocytesusing “Tripure” reagent 
(Roche Diagnostics GmbH, Mannheim, Germany), according to the 
manufacturer's instructions. The quality and quantity of the RNA were estimated 
by measuring OD at 260/ 280 nm and 260 nm respectively, using the 
“Nanodrop” (ND1000, Nano Drop Technologies Inc. Wilmington, DE, USA). Up 
to 2 μg of total RNA was reverse transcribed with random primers, using the 
“High Capacity cDNA Reverse TranscriptionKit” (Applied Biosystems, Foster 
City, CA). Real-time PCR amplification of cDNA samples was performed in a 
StepOne™ Real-Time PCR System (Applied Biosystems) using TaqMan® 
Gene Expression Master Mix, primers and probes provided by Applied 
Biosystems. Expression of FAS was measured with TaqMan expression assay 
(ID: Hs00236330_m1) from Applied Biosystems. 
GAPDH gene was selected for normalization from a set of 4 housekeeping 
genes, ACTB,GAPDH, HPRT and 18S, since it presents higher stability among 
the MDD samples (data not shown). Samples were subdivided into groups 
according to their FAS -670A>G genotypes to compare FAS expression levels 
within them. Relative quantification of the target transcript is based on the mean 
cycle threshold deviation of AA and AG+GG groups, normalized by reference 
transcripts. This relative expression analysis was performed using the REST 
2009 Software, ver. 2.0.13 
(http://www.qiagen.com/Products/REST2009Software.aspx?r=8042). The 
efficiency of the amplification reaction for each primer-probe is above 95% (as 
determined by the manufacturer). 
3. Statistical analysis 
Data preparation and analysis was carried out using the computer software IBM 
Statistical Package for Social Sciences – SPSS for Windows (version 22.0) and 
Epi Info (version 6.04a). A 5% level of significance was used in the Chi-square 
(χ2) analysis to compare the categorical variables. Odds ratio (OR) and 95% 
confidence interval (CI) were calculated as a measure of association between 
genotypes and the evaluatedphenotypes development risk. Fisher's Exact Test 
was used for tables containing cells where values are less than 5 individuals. 
Kaplan-Meier survival curves were used to evaluate correlation between 
genotypes and time to relapse and were compared by Breslow statistical test. 
Further, multiple Cox regression analysis was used to assess the effect of the 
evaluated polymorphisms on the time to relapse after AD treatment and to 
adjust for potential confounders. 
Pair Wise Fixed Reallocation Randomization Test ©, calculated by REST 
software, was used to determined the relative gene expression between 
genotype groups. This tool integrates randomization and bootstrapping methods 
that test the statistical significance of calculated expression ratios by the 
hypothesis test p(H1) representing the probability of the alternate hypothesis 
that the difference between groups is due only to chance (Pfaffl et al., 2002). 
A posteriori power analysis was performed using Quanto software (version 
1.0; http://hydra.usc.edu/gxe). The size of our sample is sufficient to detected 
association effects for the studied SNPs of at least 2.8 OR, with a statistical 
power of 80% and a maximal experimental-wise alpha error of 5%. 
4. Results 
4.1. Antidepressant response phenotypes 
The clinical and socio-demographic variables are presented in Table 1. 
Remission was reported in 61 patients (76.25%), from this 16 remitters (20.0%) 
presented relapse. Nineteen patients (23,8%) were unable to respond to two 
trials of different drugs and presented Treatment Resistant Depression. It was 
considered that patients presenting relapse or TRD, belong to a Bad Prognosis 
group, which represented 43.8% (35 patients). 
 
  
4.2. Genotype frequencies of FAS and FASL polymorphisms and 
treatment outcome 
The genotype distribution of FAS -670G>A and FASL -844T>C polymorphisms 
were evaluated among the different treatment response phenotypes (Table 2). 
No significant deviations from the Hardy–Weinberg equilibrium proportions were 
observed for bothSNPs (p>0.05). 
 
 
Our results revealed that patients carrying FAS -670 AG or GG genotypes are 
more prone to have poor prognosis (relapse or TRD: OR=6.200; 95% CI: 
[1.875–20.499];p=0.001; Table 2). We also observed that patients carrying 
these genotypes (AG or GG) have a higher risk to develop TRD (OR=10.895; 
95%CI: [1.362–87.135]; p=0.008; Table 2) when compared with remitters. 
Moreover when compared with patients exhibiting remission without relapse, 
patients carrying AG and GG genotypes present a 14-fold increased risk of 
developing TRD (OR=14.40, 95% CI:[1.76–117.4]; p=0.003). 
Despite not influencing the risk of relapse, FAS -670A>G polymorphism seems 
to influence time to relapse after AD treatment. Kaplan–Meier analysis (Fig. 1) 
revealed that carriers of the FAS -670 AG or GG genotypes seem to relapse 
after 88 weeks, while patients carrying AA genotype relapse after 100 weeks 
(p=0.032, Breslow test). Moreover, multivariate analysis adjusted to potentials 
confounders (gender, age, school years and marital status) showed that 
patients carrying AG or GG genotypes have higher risk to early relapse 
(HR=3.827; 95% CI: [1.072–13.659]; p=0.039). 
 
  
Regarding FASL -844T>C genetic polymorphism no association was found 
between genotypes and any of the studied treatment phenotypes. 
4.3. Peripheral Fas mRNA expression 
To verify whether the different FAS -670A>G genotypes modulate the 
expression of FAS transcripts, we evaluated mRNA expression by quantitative 
real-time PCR in the peripheral blood of MDD patients whose RNA samples 
were available (38 individuals). Results demonstrated a decrease in FAS 
expression among AG+GG carriers, whose genotypes were more common in 
TRD patients (Fig. 2). In this group of patients, FAS mRNA was down-regulated 
(in comparison to carriers of AA genotype) by a fold of change of 0.628 
(p=0.032; 95% CI: [0.070–5.732]). 
 
 5. Discussion 
Our data suggests an association of FAS -670A>G genetic polymorphism with 
resistance to antidepressant treatment and poor prognosis in depressed 
patients. Moreover, we also observed an association of this polymorphism and 
time to relapse. Additionally, we detected that Fas mRNA levels were 
downregulated in patients carrying AG+GG genotype configuration. These 
results point towards a putative connection between decreased FAS activity and 
impaired antidepressant treatment response. 
Genetic polymorphisms in FAS gene have been associated with treatment 
resistant schizophrenia ( Jia et al., 2011), Alzheimer disease (Erten-Lyons et al., 
2010) and cancer (Han et al., 2013), but never have been studied in depression 
and antidepressant response. In this context, we evaluated the role 
of FAS and FASL polymorphisms in antidepressant treatment response in a 
cohort of depressed patients with a 27 month follow up. 
Our results revealed that patients carrying FAS -670 AG or GG genotypes are 
more prone to have poor prognosis and have a higher risk to develop TRD. 
Functional studies of FAS gene showed that the -670A to G transition in the 
promoter region of FAS disrupt a STAT1 transcription factor binding site, which 
diminish the promoter activity and consequently down-regulate gene expression 
( Huang et al., 1997 and Sibley et al., 2003). These evidences suggest that the 
lack of remission may be associated with a reduced Fas receptor expression, 
originated from decreased activity of FAS gene promoter. So, how can a low 
expression of Fas, a molecule naturally involved in apoptotic cascades, could 
be a factor associated with Treatment Resistant Depression and poor 
prognosis? 
Fas has been known to be broadly expressed in the brain, particularly in the 
hippocampus and cerebral cortex (Beier and Schulz, 2009). Besides regulating 
apoptosis, recent evidences implicate Fas in neurogenesis activation, both in 
healthy and injured brain, and in neuronal branching of mature neurons (Corsini 
et al., 2009 and Zuliani et al., 2006). Studies of Zuliani et al. (2006) have shown 
that differential trigger of Fas neurite remodeling cascade or Fas apoptosis 
cascade is related with the surrounding milieu. These authors argued that 
factors present in the injured CNS, such as reactive oxygen species, increased 
lactate or decreased ATP levels might sensitize the cell to Fas-induced 
apoptosis (Zuliani et al., 2006). Alternatively, under the influence of other 
extracellular factors, such as neurotrophins, slits, ephrins and integrins, neurons 
may undergo synaptic reorganization in the presence of FasL (Zuliani et al., 
2006). In this context, low expression of Fas can be responsible for impaired 
neuroplasticity, characterized by cognitive deficits, pyramidal neuron dendrites 
atrophy, reduced dendritic branches and delayed neurite regeneration, which 
has been observed has in FAS deficient mice (lpr) (Lambert et al., 
2003 and Zuliani et al., 2006). 
These observations are consistent with the downregulation of FAS expression 
found among AG+GG carriers, whose genotypes were more common in TRD 
patients. A paper from Banzato, et al., (2013) also found lower FAS mRNA 
levels among GG genotype carriers. Further evidence for a functional role of 
Fas in this context was reported elsewhere describing an increase expression in 
Fas plasma membrane of 31% upon antidepressant treatment ( Xia et al., 
1996). 
Besides being linked with antidepressant treatment resistance, we also 
observed that individuals carrying FAS -670 AG or GG genotypes develop 
treatment relapse earlier than the one that present FAS -670AA genotype. 
Patients carrying these genotypes also have higher risk to early relapse 
(HR=3.827). This result reinforces the impact of FASgene polymorphism in 
treatment outcome, specifically the putative impact of Fas in neuronal 
remodeling. 
With these evidences and our results we were able to think that Fas/FasL 
system seems to be involved in Treatment Resistant Depression, and this 
condition could hypothetically result of an incomplete reestablishment of 
neurogenesis/synaptic plasticity network, due to the reduced levels of Fas 
expression promoted by FAS -670G allele. Our hypothesis is in accordance with 
what is proposed by others authors, which have reported several neuroplasticity 
and proliferation-related intracellular pathways to be involved in antidepressant 
mechanism of action, among these Brain-derived neurotrophic factor (BDNF), 
b-catenin and mammalian TOR ( Pilar-Cuellar et al., 2013). 
The present study has some obvious limitations. First limitation is related with 
the use of drugs with different mechanisms of action, which difficult the 
interpretation of the effect of studied polymorphisms on a specific drug. 
However patients were treated according to the Texas Medication Algorithm 
and this approach is more similar to the real word, since most of the time 
patients are treated with different drugs and still display treatment resistance. 
Other limitation is related with the sample size issue. However, this study might 
be, to the best of our knowledge, the largest one studding the influence of 
genetic variants in antidepressant response in Portuguese population. 
Nevertheless, and despite sample size, the calculated statistical power is still 
sufficient to detect the magnitude of the effect reported. In order to overcome 
this limitation, further studies with larger sample size are required to reinforce 
the evidences we presented. The third limitation is related with the fact that we 
correlated FAS genotypes with peripheral levels of FAS transcripts, not with 
brain transcript levels. However, as far as we know, there are no evidences 
linking Fas expression in the brain upon antidepressant treatment. FASmRNA 
expression in hippocampus and pre-frontal cortex of postmortem tissue of 
depressed patients, undergoing antidepressant treatment, could be used to 
confirm the evidences presented herein. 
To the best of our knowledge, this is the first study to evaluate the role 
of FAS functional polymorphism in the outcome of antidepressant therapy. Our 
results demonstrate thatFAS -670A>G genetic polymorphism has a role in 
antidepressant treatment response in our subset of MDD patients. This result 
might be explained by the putative influence of Fas in neurogenesis and/or 
neuroplasticity network, whose reestablishment is known to be essential for AD 
therapeutic effect. Due to growing progresses in this area, this marker should to 
be integrated with others to detect the genetic susceptibility of complex 
conditions, such as Treatment Resistant Depression. 
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